New opportunities to use a lipoprotein(a) blood test in real-life clinical practice. Resolution of the expert council
Authors:   Research Institute for Therapy and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of the RAS, Novosibirsk, Voevoda M.I. , Ezhov M.V. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Konovalov G.A. ,   JSC «MEDSI Group of Companies», Moscow, Zheleznyakova I.A. ,   Center for Healthcare Quality Assessment and Control, Moscow, Pokrovsky S.N. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Alieva A.S. ,   V.A. Almazov National Medical Research Center, St. Petersburg, Barbarash O.L. ,   Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Vorobyev A.S. ,   Surgut State University, Surgut, Gornyakova N.B. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Kashtalap V.V. ,   Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Kalacheva O.S. ,   JSC «MEDSI Group of Companies», Moscow, Korennova O.Yu. ,   Omsk State Medical University, Omsk, Polyakova E.A. ,   Pavlov First Saint-Petersburg State Medical University, St. Petersburg, Shalnova S.A. ,   National Medical Research Center of Therapy and Preventive Medicine, Moscow, Shakhnovich R.M. ,   Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Yanishevsky S.N. ,   V.A. Almazov National Medical Research Center, St. Petersburg
Published: January 2025

On May 14, 2024, a meeting of the Expert Council of Leading Lipid Metabolism Disorder Specialists to discuss several issues related
to elevated lipoprotein(a) [Lp(a)] blood level (i. e., an important risk factor for atherosclerotic cardiovascular diseases [ ASCVD]) was
held in Moscow. The Expert Council Resolution includes following key points: 1) both terms «lipoproteid(a)» and «lipoprotein(a)» may
be used currently; 2) Lp(a) measurement units should be universal (without conversion formulas). It is now acceptable to present Lp(a)
levels in different units: nmol/L, mg/dL; 3) for a more comprehensive assessment of the risk of new, future cardiovascular complications,
including its restratification in primary prevention, it is recommended to measure Lp(a) as part of a standard lipid profile; 4) Lp(a)
measurement is mandatory in patients with STEMI/non-STE acute coronary syndrome, ischemic stroke/transient ischemic attack or with
verified atherosclerosis of peripheral arteries, as well as in those with a family history of ASCVD; 5) we recommend these statements to be
considered for inclusion to the next revision of Lipid Metabolism Disorders Clinical Guidelines (including Medical Care Quality Assessment
Criteria), as well as in the next revision of clinical guidelines such as Ischemic Stroke and Transient Ischemic Attack in Adults, STEMI/non-
STEMI, and Stable Ischemic Heart Disease.
Keywords: atherosclerotic cardiovascular diseases, lipoprotein(a), Expert Council.
For citation: Voevoda M.I., Ezhov M.V., Konovalov G.A., Zheleznyakova I.A., Pokrovsky S.N., Alieva A.S., Barbarash O.L., Vorobyev A.S.,
Gornyakova N.B., Kashtalap V.V., Kalacheva O.S., Korennova O.Yu., Polyakova E.A., Shalnova S.A., Shakhnovich R.M., Yanishevsky S.N.
New opportunities to use a lipoprotein(a) blood test in real-life clinical practice. Resolution of the expert council. RMJ. 2024;9:40–44. DOI:
10.32364/2225-2282-2024-9-7